OR WAIT null SECS
September 17, 2020
The Russian Direct Investment Fund has announced three deals with India, Brazil, and Mexico, for the supply of doses of Sputnik V, a potential COVID-19 vaccine.
September 16, 2020
Valneva will supply the UK government with an initial 60 million doses of the vaccine in the second half of 2021, if successful, and will provide more doses thereafter.
The funding will help advance the vaccine’s clinical evaluation, potential marketing authorization, development and manufacturing in Germany, and the number of participants in late-stage clinical trials.
September 15, 2020
GenSight Biologics has submitted a marketing authorization application to the European Medicines Agency for Lumevoq.
Vizibl and Sanofi have entered into a Phase I partnership to streamline processes around supplier management.
September 13, 2020
Clinical trials for AZD1222 coronavirus vaccine resume in the UK as per guidance by MHRA.
September 09, 2020
PRAC has recommended the marketing authorization of ulipristal acetate for the treatment of uterine fibroids be revoked.
ECCRT and IDDI have established a partnership for the continuous development of IDDI global team members.
Imfinzi has been granted approval in the EU for the treatment of adults with extensive-stage small cell lung cancer.
CPhI has released the agenda for its forthcoming two-week virtual event, CPhI Festival of Pharma.